LAS VEGAS, NV--(Marketwire - June 04, 2009) -
Highlighted Links |
Gamma Pharmaceuticals Inc. |
The new purchase orders represent a significant increase in Gamma's market share. Gamma's brands are cited by consumers as being equal to or better than similar offerings from Pfizer, Johnson & Johnson and Bayer Xetra, BAYG.X.
Gamma Pharmaceuticals Inc. is a marketing and product formulation company. The Company creates, registers and brands innovative product lines, including Nutritional Supplements, Personal Care Products and Over-The-Counter (OTC) pharmaceuticals. At present, Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize a proprietary "Gel Delivery Technology®," offering one of the most innovative gel product forms; offering consumers a more pleasant experience with product forms that absorb more rapidly, are more convenient and taste great. Market categories Gamma targets are growing as rapidly as 60% per year.
Gamma master brands include: Brilliant Choice®, a range of children's vitamins, nutritional supplements and immune boosters, and Savvy®, a range of adult vitamins, nutritional supplements and immune boosters. Youth targeted products are sold as Jugular® Energy - "Go for the Jugular"™; and iceDROP Instant Hand Sanitizer™ (Beijing). In addition, Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma holds licenses for 9 SKUs in China.
Forward-Looking Statements: This news release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Such statements are subject to certain risks and
uncertainties, and actual circumstances, events or results may differ
materially from those projected in such forward-looking statements. The
Company cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically disclaims any
obligation, to update or revise such statements to reflect new
circumstances or unanticipated events as they occur.
Contact:
Gamma Pharmaceuticals Inc.
Joe Cunningham
Office: 702 989 5262
Direct: 651 204 2048